tirzepatide surpass-4 reduces albuminuria among adults with type 2 diabetes in SURPASS trials Tirzepatide's Surmount-4 Trial Reveals Groundbreaking

It binds to glucose-dependent insulinotropic polypeptide (GIP) receptors and glucagon-like peptide-1 (GLP-1) receptors

Please note: Compounded medications are tailored to individual needs or used in case of shortages, but they are not FDA-approved for safety or effectiveness

[3,5] The day of weekly administration can be changed, if necessary, as long as the time between the two doses is at least 3 days (72 hours) [1] Storage Store in refrigerator Pens can be stored at room temperature for up to 21 days [1] LONG-TERM SAFETY Tirzepatide was FDA-approved in 2022

The three most common causes of GLP-1-related oral odor are belching, bad breath (halitosis), and ketosis, McGowan says

Healthcare providers can assess injection technique, review site rotation practices, and consider whether alternative treatment options might be better tolerated